
Surrozen

Restoring Vision Through the Science of Renewal



November 2026

Legal Disclaimers

This presentation contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as “will,” “plan,” “intend,” “potential,” “expect,” “anticipate”, “could,” or the negative of these words and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Surrozen’s discovery, research and development activities, in particular its development plans for its product candidates (including anticipated clinical development plans and timelines, the availability of data, the potential for such product candidates to be used to treat human disease or address unmet needs in serious eye disease, as well as the potential benefits of such product candidates) and Surrozen’s partnership with Boehringer Ingelheim, including the potential for future success-based development, regulatory, and commercial milestone payments, in addition to mid-single digit to low-double digit royalties on sales. These statements are based on various assumptions, whether or not identified in this presentation, and on the current expectations of the management of Surrozen and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Surrozen. These forward-looking statements are subject to a number of risks and uncertainties, including the initiation, cost, timing, progress and results of research and development activities, preclinical and clinical trials with respect to its product candidates, and potential future drug candidates; Surrozen’s ability to fund its preclinical and clinical trials and development efforts, whether with existing funds or through additional fundraising; Surrozen’s ability to identify, develop and commercialize drug candidates; Surrozen’s ability to successfully enroll participants and complete preclinical and clinical studies for its product candidates; the effects that arise from volatility in global economic, political, regulatory and market conditions; and all other factors discussed in Surrozen’s Annual Report on Form 10-K for the year ended December 31, 2025 and Surrozen’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026, June 30, 2026, and September 30, 2026 filed with the Securities and Exchange Commission ("SEC") under the heading “Risk Factors,” and other documents Surrozen has filed, or will file, with the Securities and Exchange Commission. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Surrozen presently does not know, or that Surrozen currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Surrozen’s expectations, plans, or forecasts of future events and views as of the date of this presentation. Surrozen anticipates that subsequent events and developments will cause its assessments to change. However, while Surrozen may elect to update these forward-looking statements at some point in the future, Surrozen specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Surrozen’s assessments of any date after the date of this presentation. Accordingly, undue reliance should not be placed upon the forward-looking statements. This presentation is not an offer to sell, a solicitation of an offer to buy or a recommendation to purchase any security, nor is it a solicitation of a proxy, consent or authorization with respect to any securities transaction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.

© 2026 Surrozen, Inc.

Designing Best-in-Disease Multi-Functional Antibodies for Retinal Vascular Disease

Problem

Suboptimal treatment response and durability with current treatments for retinal vascular disease (~$15B market[1])

Hypothesis

Combining vascular restoration through Wnt agonism with VEGF inhibition may provide differentiated clinical activity beyond current anti-VEGF therapies

Assets

SZN-8141 — Wnt agonism + VEGF blockade

SZN-8143 — Wnt agonism + VEGF & IL-6 blockade

Clinical Strategy

DUET Ph1b/2a study evaluates safety and dose selection, with a head-to-head benchmark against an active comparator

Value Creation

Opportunity for best-in-disease therapeutic with differentiated anatomic control, durability, and reperfusion

Expected Key Milestones

SZN-8141 Phase 1b topline data
Second half 2027

SZN-8141 Phase 2a topline data
2028


Source: 1. Straights Research Anti-VEGF Therapeutics Market Size, September 2026.

© 2026 Surrozen, Inc.

Retinal Vascular Diseases (DME, wet AMD) are Large and Growing Markets with Significant Unmet Need

	Retinal Vascular Diseases
US Prevalence[1]	2.7M
Global Prevalence[2,3]	>40M
Global Anti-VEGF Market[4]	~$15B in 2025 → ~$18B in 2034
Morbidity	- DME patients incur healthcare costs 2-3x higher vs having diabetes alone[5] - AMD is major cause of sight loss in the population aged 65 years and older[6]
Key Products[1]	Anti-VEGF therapies: Faricimab, Aflibercept, Ranibizumab
Key Unmet Needs[7]	Need for better drying agents Need for longer lasting therapies Need for new therapies beyond VEGF inhibition

Global Anti-VEGF Agents Ophthalmic Drug Market Forecast




Source: 1. Health Advances DME and wet AMD primary market research for Surrozen - Nov 2024; 2. Teo et al. Ophthalmology. 2021 Nov;128(11):1580-1591; 3. Campochiaro. Invest Ophthalmol Vis Sci. 2021 Nov 1;62(14):26; 4. Straights Research Anti-VEGF Therapeutics Market Size, September 2026; 5. Choi et al. JMIR Public Health Surveill. 2024 Oct 8;10:e56741; 6. Centers for Disease Control (CDC). About Age-related Macular Degeneration. 2024; 7. ASRS PATS Survey 2025.

© 2026 Surrozen, Inc.


Vabysmo (VEGF + Ang2): Market Validation for VEGF Combinations

Multiple targets drive additional clinical benefit
Incremental drying leads to rapid adoption

Vabysmo Clinical Outcomes in DME*




Global Vabysmo Revenue



Source: Vabysmo Website; Roche Financial Reports 2022 – 2025.
*Vabysmo results and commercial performance are not indicative of potential results or commercial performance of SZN-8141.

© 2026 Surrozen, Inc.



Wnt Signaling

A Key Regulator of Vascular Biology

Surrozen

Wnt is a Key Regulator of Retinal Vascular Function

A complementary mechanism to VEGF inhibition

Genetic Validation

Mutations in FZD4 mediated Wnt signaling cause Norrie disease and FEVR — both marked by severe vascular defects


Preclinical Evidence

Wnt mimetics observed to restore vascular integrity, reduce leakage, and regenerate vasculature in models of retinal injury[1]

Clinical Evidence

Clinical activity observed in DME patients with outcomes comparable to anti-VEGF therapy[2,3]

FZD4/LRP5 Wnt Signaling Restores Blood Retina Barrier Integrity



Source: 1. Data on file; 2. EyeBio Press Release, February 13, 2024; 3. Merck Press Release, September 24, 2026.

© 2026 Surrozen, Inc.

Advancing Beyond VEGF

Combining Wnt agonism with VEGF inhibition and other complementary mechanisms to drive differentiated outcomes

Supporting Evidence

- Wnt agonism monotherapy is the only non-VEGF monotherapy to demonstrate comparable clinical efficacy to anti-VEGF in a pivotal study[1]
- Surrozen preclinical data demonstrates the synergy of Wnt agonism and VEGF inhibition in preclinical models[2]

MOA	DME Study	BCVA at week 52	CST at week 52
Wnt agonist	Remigromig Ph2/3 study[3] (2026)	+9 letters Noninferior to monthly ranibizumab 0.5mg	-140 um
Anti-IL-6	Vamikbart Ph2 study[4] (2026)	+4 letters*	-60-70 um*
Anti-Ang2	Nesvacumab Ph1 study[5]	No monotherapy data published	No monotherapy data published
Tie2 Agonist	RG6351 Ph1/2 study[6] (2025)	No monotherapy data published	30-38% CST response at 12 weeks

Comparison based on historical published data; no head-to-head studies have been conducted and cross-trial comparisons may not be reliable due to differences in trial design and patient population and characteristics.

Source: 1. Merck Press Release, October 10, 2026; 2. Data on file; 3. Merck American Academy of Ophthalmology 2026 Ph2/3 BRUNELLO Trial Presentation; 4. Roche Association for Research in Vision and Ophthalmology 2026 Ph2 ALLUVIUM Trial Presentation; 5. Clinicaltrials.gov NCT019971646; 6. Roche American Society of Retina Specialists 2025 Ph1 THAMES Trial Presentation.
*Endpoints measured were at an average of 44 and 48 weeks.

© 2026 Surrozen, Inc.

Surrozen Advantage: Defining the Next Era of Retinal Repair

Pioneers in Wnt Pathway Biology:

Built by the world's leading experts who discovered the Wnt pathway, its role in tissue restoration and ligand:receptor biology

Next Generation Multifunctional Biologics:

Multifunctional biologics which combine Wnt activation with modulation of other drivers of retinal disease (VEGF, IL-6)

Antibody Design Leadership:

Deep expertise in FZD/LRP signal modulation – multiple publications on optimizing antibody formats

Broad IP Portfolio:

Robust patent estate, including 8 issued U.S. patents and over 25 pending families globally

© 2026 Surrozen, Inc.



Our Development Pipeline

Surrozen

Second Generation Multi-Functional Wnt Targeted Antibodies

Complementary mechanisms enable potential best-in-disease antibodies

SZN-8141 – WNT Activation + VEGF Inhibition


Wnt activation via FZD4/LRP5

- Potential for best-in-class Wnt activation
- Wnt activation upregulates tight junction proteins and restores blood retina barrier function

VEGF inhibition via VEGF decoy receptors

Aflibercept sequences - comparable VEGF-A/PlGF binding affinity


- Observed to reduce neovascularization and vascular leakage



FZD4 IgG1/LRP5VHH/VEGF soluble decoy receptor


© 2026 Surrozen, Inc.

SZN-8141 Restores Retinal Vessel Architecture




Novel mechanism for treatment of retinal vascular diseases that has been observed to directly reduce leakage and eliminate pathologic leaky vessels

Oxygen Induced Retinopathy Model



Control SZN-8141




80% reduction in avascular area

****p<0.0001 v. negative control. N = 12-14 mice per group.

© 2026 Surrozen, Inc.


SZN-8141 VEGF Binding Domains Neutralize Pathologic VEGF-A



VEGF soluble decoy receptor domains bind soluble VEGF-A with comparable affinity and potency to aflibercept

In vitro assays demonstrate similar potency, affinity and binding to aflibercept

KDR/NFAT-RE HEK293 Cell Potency Assay




Binding Affinity to VEGF (Kd)

SZN-8141	Aflibercept
<1pM	<1pM


© 2026 Surrozen, Inc.

SZN-8141 Synergy Observed with Wnt and VEGF Dual Mechanism




OIR Model (Delayed)

Reduction of avascular area



Reduction of neovascularization



**p<0.01, ****p<0.0001 v. negative control; #p<0.05, ###p<0.001 v. anti-VEGF + Wnt agonist; n=7 mice for negative control and n=15 mice for active treatment groups. Anti-VEGF is SZN-8141 with mutations to eliminate Wnt activity; Wnt agonist is SZN-8141 with mutations to eliminate anti-VEGF activity.

© 2026 Surrozen, Inc.

DUET: A Phase 1b/2a Study of SZN-8141 in Diabetic Macular Edema

Phase 1b topline data expected in 2H 2027, with Phase 2a topline data expected in 2028

Phase 1b First-in-Human

Single ascending dose

- Open-label single-ascending-dose cohorts in DME
- 3-month observation after each dose
- Identifies dose levels for randomized efficacy evaluation
- Population: treatment-naïve and previously treated DME
- *Currently enrolling patients*

Phase 2a Dose Expansion

Randomized, head-to-head vs. Vabysmo

- Randomized, double-masked study in treatment-naïve and previously treated DME patients: two SZN-8141 doses vs. Vabysmo 6mg
- Approximately 50 participants per arm (~150 total); 3 monthly injections with 4-month observation period to assess durability of effect
- Primary analysis at Week 12 designed to inform initiation of potential registrational program

Study design — IVT dosing schedule by treatment arm (Weeks 0–24)

Weeks	0	4	8	12	16	20	24 (EOS)
SZN-8141 high dose	IVT	IVT	IVT	Obs	Obs	Obs	Obs
SZN-8141 mid dose	IVT	IVT	IVT	Obs	Obs	Obs	Obs
Vabysmo 6mg	IVT	IVT	IVT	Obs	Obs	Obs	Obs

IVT injection

Observation

Primary endpoint: Safety and tolerability

Select secondary and exploratory endpoints: Best-corrected visual acuity (BCVA), optical coherence tomography (OCT), OCT-angiography (OCT-A), ultra-widefield fluorescein angiography, immunogenicity, PK

DUET
DME Clinical Trial

© 2026 Surrozen, Inc.

SZN-8143: Targeting IL-6 Could Provide Additional Clinical Benefit in UME and Other Retinal Vascular Diseases


SZN-8143 – WNT + VEGF + IL-6

Wnt activation via FZD4/LRP5 Fv:VHH

IL-6 inhibition via anti-IL-6 IgG

- Reduces vascular permeability and VEGF production

VEGF inhibition via VEGF decoy receptors



IL-6 IgG1/LRP5VHH/FZD4 Fv/VEGF soluble decoy receptor

Additional Fc engineering to reduce liabilities

Fc and FcRn mutations to eliminate effector function (LALAPG) and reduce systemic exposure (AAA)

© 2026 Surrozen, Inc.

Wnt Biology Supports Multiple Therapeutics Opportunities in Ophthalmology

Pipeline Wnt agonists show promising preclinical activity across multiple disease models

Fuchs' Endothelial Dystrophy Program

- Loss of corneal endothelial cells causes corneal swelling, haziness and vision loss, accompanied by ECM deposition ("guttata")
- Development stage candidate demonstrated preclinical activity suggesting:
  - Robust reduction in central corneal thickness
  - Rapid improvement in corneal clarity
  - Stimulation of proliferation in human cornea cultures

Geographic Atrophy Program

- Advanced form of macular degeneration that leads to progressive loss of central vision due to the degeneration of retinal cells
- Candidate demonstrated preclinical activity demonstrating:
  - Neuroprotection in acute injury and progressive degeneration models of photoreceptor damage
  - Stimulation of RPE proliferation and differentiation in vitro


Retinitis Pigmentosa Program

- A group of genetic retinal disorders leading to degeneration of photoreceptors
- Candidate demonstrated preclinical activity demonstrating impact on muller glial cells and photoreceptors

© 2026 Surrozen, Inc.

Ophthalmology Franchise: Multiple Novel Candidates

PROGRAM	INDICATION	RESEARCH	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3
SZN-8141 FZD4, VEGF	wet AMD, DME					
SZN-8143 FZD4, VEGF, IL-6	wet AMD, DME, UME					
Research	Ocular disease					
SZN-413* FZD4	Retinopathies					



Glossary: FZD - frizzled; VEGF - Vascular Endothelial Growth Factor; IL-6 – interleukin-6; AMD - Age-related Macular Degeneration; DME – Diabetic Macular Edema; UME – Uveitic Macular Edema

*Licensed to Boehringer Ingelheim.

© 2026 Surrozen, Inc.

Surrozen: Developing the Next Generation of Retinal Therapeutics

1

Differentiated approach

Wnt biology offers a differentiated therapeutic approach in retina

2

First-in-class biologics

SZN-8141 is a novel biologic combining Wnt agonism and VEGF inhibition in a single molecule

3

Best-in-disease potential


DUET is designed to determine whether this biology can translate into clinically meaningful outcomes

© 2026 Surrozen, Inc.

Surrozen

Thank You

www.surrozen.com



Glossary

AMD	Age-related macular degeneration	**IVT**	Intravitreal
BCVA	Best-corrected visual acuity	**Lrp**	Lipoprotein receptor-related protein
CST	Central subfield thickness	**PK**	Pharmacokinetics
DME	Diabetic macular edema	**POC**	Proof-of-concept
ECM	Extracellular matrix	**OIR**	Oxygen induced retinopathy
EOS	End of study	**RLU**	Relative light units
FEVR	Familial exudative vitreoretinopathy	**RPE**	Retinal pigment epithelium
FZD	Frizzled	**UME**	Uveitic macular edema
IgG1	Immunoglobulin G1	**VEGF/R**	Vascular endothelial growth factor/receptors
IL-6	Interleukin 6	**Wnt**	Wingless-related integration site

© 2026 Surrozen, Inc.